Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients.
Anti-rejection therapy
Enzyme induction
Lung adenocarcinoma
Solid organ transplantation
Sotorasib
Journal
Transplant immunology
ISSN: 1878-5492
Titre abrégé: Transpl Immunol
Pays: Netherlands
ID NLM: 9309923
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
30
05
2022
revised:
20
07
2022
accepted:
20
07
2022
pubmed:
29
7
2022
medline:
17
8
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
The management of immunosuppressors in solid organ transplantation requires pharmacological therapeutic monitoring with regular adaptation of the dosage to the residual level. An obvious cause of these fluctuations is drug interactions, particularly for mTOR inhibitors and anti-calcineurin drugs, which are highly metabolized by cytochromes P450. A 72-year-old lung transplanted man, treated by tacrolimus and everolimus in the long term, had his residual immunosuppressor levels unbalanced by the introduction of sotorasib, which is used for metastatic pulmonary adenocarcinoma. This imbalance is explained by the fact that sotorasib is an inducer of CYP3A4 and an inhibitor of PGP, but the strength of the interaction has never been studied. This will have required a threefold increase in dosages and weekly monitoring before satisfactory residual levels were achieved.
Identifiants
pubmed: 35901952
pii: S0966-3274(22)00152-6
doi: 10.1016/j.trim.2022.101678
pii:
doi:
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Piperazines
0
Pyridines
0
Pyrimidines
0
sotorasib
2B2VM6UC8G
Everolimus
9HW64Q8G6G
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101678Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.